Home > Drugs A – Z > Alpha-1 Proteinase Inhibitor Human...

Alpha-1 Proteinase Inhibitor Human (Intravenous route)

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Alpha-1 proteinase inhibitor injection, also called alpha 1-PI, is used to treat a certain type of emphysema (a lung condition). The emphysema is caused by the lack of a protein called alpha 1-antitrypsin (AAT) in the body. This medicine replaces the protein when the body does not produce enough. This medicine is to be given only by or under the immediate supervision of your doctor… Read more
Brand names include
Aralast, Aralast NP, Glassia, Prolastin, Prolastin-C, Zemaira
Drug classes About this
Blood Modifier Agent

What works? Research summarized

Evidence reviews

Alpha‐1 proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants

There is not enough evidence to show the long term effect of using Alpha‐1 proteinase inhibitor for chronic lung disease in premature babies. Inflammation of the lungs is one of the causes of chronic lung disease (CLD) in babies born before 37 weeks. Babies with CLD need extra oxygen and the disease can also cause serious long‐term problems. Lung damage is caused by the release of enzymes and other anti‐oxidants because babies with CLD have a low level of Alpha‐1 proteinase inhibitor (a1P1), a substance that stops lung tissue being destroyed. A medication version of AlP1 is sometimes given to protect their lungs. The review of the trials found that there is not enough evidence to show long term beneficial effects of a1P1. More research is needed.

Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis

The authors concluded that augmentation therapy slowed lung function decline in patients with alpha1-antitrypsin deficiency, with patients with moderate obstruction (forced expiratory volume in one second of 30 to 65%) most likely to benefit. Much of the review was well-conducted, but reliance upon predominantly non-randomised studies of unknown quality made it difficult to confirm the reliability of these conclusions.

Tamper-Resistant Oxycodone: A Review of the Clinical Evidence and Cost-effectiveness [Internet]

Requiring tamper-resistant properties for products that contain particular controlled substances in order to be sold can be part of efforts to address prescription drug abuse. The purpose of this review is to evaluate the effectiveness of tamper-resistant formulations in curbing abuse and misuse of oxycodone.

See all (18)

Summaries for consumers

Alpha‐1 proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants

There is not enough evidence to show the long term effect of using Alpha‐1 proteinase inhibitor for chronic lung disease in premature babies. Inflammation of the lungs is one of the causes of chronic lung disease (CLD) in babies born before 37 weeks. Babies with CLD need extra oxygen and the disease can also cause serious long‐term problems. Lung damage is caused by the release of enzymes and other anti‐oxidants because babies with CLD have a low level of Alpha‐1 proteinase inhibitor (a1P1), a substance that stops lung tissue being destroyed. A medication version of AlP1 is sometimes given to protect their lungs. The review of the trials found that there is not enough evidence to show long term beneficial effects of a1P1. More research is needed.

PubMed Health Blog...

read all...